Matthew McClure has been appointed executive vice president and chief medical officer of South San Francisco-based Aligos Therapeutics. He was most recently the chief medical officer of Second Genome. McClure’s experience also includes time at InterMune, which was acquired by Roche in 2014. Preclinical-stage Aligos is developing treatments for liver diseases and viral infections.
Sponsored · Whitepaper
New approaches & tech are on the horizon that could change how researchers and clinicians approach brain and neurological disorders
Sponsored · Whitepaper
CMC in Drug Development and Life Cycle Management
PRA Health Sciences
Sponsored · Webinar
Phenotypic Screening & Profiling to Understand a Compound's Disease Impact
Eurofins Discovery
